Renewing health


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Renewing health

  1. 2. <ul><li>RENEWING HEALTH aims at implementing large-scale real-life test beds for the validation and subsequent evaluation of innovative telemedicine services using a patient-centred approach and a common rigorous assement methodology </li></ul><ul><li>Involving 7800 patients </li></ul><ul><li>Start 2010-02-01-2012-08-31 </li></ul>
  2. 3. Clinical objectives <ul><li>The project improves the quality of life of patients suffering from diabetes, chronic obstructive pulmonary or cardiovascular diseases. </li></ul>
  3. 4. Patient/user perspective objectives <ul><li>The project will provide coherent clinical services through ICT that take into consideration patients’ and professional users’ needs, capabilities, risks and benefits. </li></ul>
  4. 5. Economic objectives <ul><li>The project implements a new healthcare model that is expected to reduce the cost of chronic patients care to the society </li></ul>
  5. 6. Organisational objectives - <ul><li>The project intends to create an organisational model for telemedicine services that ensures a safe, clear and efficient pathway for patients </li></ul>
  6. 7. 9 regions in Europe <ul><li>Norrbotten (Sweden) </li></ul><ul><li>Northern Norway (Norway) </li></ul><ul><li>South Karelia (Finland) </li></ul><ul><li>Carinthia (Austria) </li></ul><ul><li>Berlin (Germany) </li></ul><ul><li>Thessaly (Greece) </li></ul><ul><li>Region of Southern Denmark </li></ul><ul><li>Veneto (Italy) </li></ul><ul><li>Catalonia (Spain) </li></ul>
  7. 8. Clusters <ul><li>Regions are divided in 7 clusters based on similarities in interventions and chronic conditions. </li></ul><ul><li>The project in Norrbotten is in two cluster; diabetes and cardivascular diseases </li></ul>
  8. 9. The project in Norrbotten The Diabetes Epidemic and tele-enabled integrated care <ul><li>The prevalence of diabetes type II is rising. In Norrbotten the prevalence is 7% of the population. </li></ul><ul><li>Diabetes II is treated mainly by life-style interventions in diet, smoking and physical activity, supported by medical treatment. </li></ul><ul><li>The aim of the treatment is to lower blood glucose, lipids, blood pressure and weight. </li></ul>
  9. 10. The project in Norrbotten The Diabetes Epidemic and tele-enabled integrated care <ul><li>Self-management support is established as an evidence-based intervention for diabetes and it has been concluded that self-management support is effective </li></ul>
  10. 11. <ul><li>To improve patients HbA1c and their health-related quality of life by providing them with technology </li></ul><ul><li>Trial start and end: 01.02.2011 – 31.07.2012 </li></ul>Objective
  11. 12. The intervention <ul><li>Participants use their own PC or receive an Android-based tablet PCs (ViewSonic ViewPad 7) with a dedicated software that manages the collection and transmission of their diagnostic measurements. </li></ul><ul><li>An integrated local health application to The National Patient Portal “My health Care Contacts” </li></ul>
  12. 13. Study type <ul><li>Randomised parallel group non-blinded trial with an intervention group and a control group (routine care only). </li></ul><ul><li>Four primary healthcare centres </li></ul><ul><li>Sample size: 200 / 200 </li></ul>
  13. 14. Inclusioncritera <ul><li>T2DM diagnosed > 3 months prior to the enrolment </li></ul><ul><li>HbA1c > 53mmol/mol </li></ul><ul><li>Age > 18 years </li></ul><ul><li>Capability of filling questionnaires by their own language </li></ul><ul><li>Being able to use the devices provided </li></ul><ul><li>Being cognitively able to participate </li></ul><ul><li>Absence of severe comorbidity </li></ul><ul><li>Not pregnant </li></ul>
  14. 15. Evaluation <ul><li>The evaluation using as a basis the MAST (Model for Assessment of Telemedicine) assessment model. </li></ul><ul><li>Primary outcome: Health-related quality of life (measured with SF-36) (beginning and trial end HbA1c (beginning and trial end) </li></ul>
  15. 16. Evaluation <ul><li>Secondary outcome: </li></ul><ul><li>Socio-demographic and clinical baseline characteristics </li></ul><ul><li>Economical: All costs of the organisation calculated for both intervention and control groups. </li></ul><ul><li>Patient perception: the WSD questionnaire </li></ul>
  16. 17. Thank you for listening Inger Lindberg, assistant professor, RNM, PhD